BMI1 and leiomyosarcoma: Epigenetic modifications are reversible changes, rendering therapeutic inhibition of their regulatory factors attractive; for example, the BMI1 inhibitor PTC-596 is currently in Phase 1 clinical trials39 in adults with solid tumors, such as leiomyosarcoma and in children with DIPG and high grade glioma.